A Phase 3 interventional study of 13 valent Pneumococcal Conjugate Vaccine and 23vPS in Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 58 sites in 2 countries. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-14.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 8th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 70 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 6 started in 2007.
This study's enrollment of 938 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 20th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 3, and was the 18th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Receives 13vPnC at year 0 and 13vPnC at year 1
Biological: 13 valent Pneumococcal Conjugate Vaccine
Receives 23vPS at year 0 and 13vPnC at year 1
Biological: 23vPS
0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after Vax 1 / Year 0
Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.
Time frame: Baseline, 1 month after Vax 1 / Year 0
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.
Time frame: 1 month after Vax 1 / Year 0
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.
Time frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Time frame: Days 1 through 14 / Year 0
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Time frame: Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Time frame: Days 1 through 14 / Year 0
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Time frame: Days 1 through 14 / Year 1
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
Time frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
| Milestone | 13vPnC / 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Started | 464 | 474 |
| Received vax 1 | 463 | 473 |
| Completed | 391 | 404 |
| Not completed | 73 | 70 |
| Withdrew: Randomized, not treated | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: 6-month contact; withdraw before vax 2 | 64 | 59 |
| Milestone | 13vPnC / 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Started | 391 | 404 |
| Received vax 2 | 391 | 404 |
| Completed | 387 | 402 |
| Not completed | 4 | 2 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Vax 2; withdraw before 6-month contact | 2 | 1 |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC | 23vPS |
|---|---|---|
| Serotype 1 | 81 (68.4 to 95.9) | 55 (46.2 to 64.8) |
| Serotype 3 | 55 (47.7 to 62.9) | 49 (42.9 to 56.9) |
| Serotype 4 | 545 (441.9 to 672.3) | 203 (157.1 to 262.2) |
| Serotype 5 | 72 (59.7 to 86.6) | 36 (29.5 to 43.1) |
| Serotype 6B | 1261 (1024.7 to 1552.6) | 417 (330.5 to 526.7) |
| Serotype 7F | 245 (191.9 to 312.4) | 160 (123.5 to 207.9) |
| Serotype 9V | 181 (138.0 to 237.0) | 90 (67.8 to 119.7) |
| Serotype 14 | 280 (227.5 to 345.5) | 285 (228.9 to 354.3) |
| Serotype 18C | 907 (761.9 to 1080.1) | 481 (385.1 to 600.7) |
| Serotype 19A | 354 (307.7 to 408.4) | 200 (170.0 to 234.4) |
| Serotype 19F | 333 (273.2 to 404.8) | 214 (174.3 to 262.8) |
| Serotype 23F | 158 (126.0 to 198.6) | 43 (34.2 to 53.5) |
OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection. Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.
| observed percentage of participants | 13vPnC | 23vPS |
|---|---|---|
| Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0) | 71.1 (66.4 to 75.4) | 27.3 (23.0 to 31.8) |
Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype. Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.
| geometric mean titer | 13vPnC | 23vPS |
|---|---|---|
| Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0) | 903 (726.7 to 1121.3) | 94 (74.1 to 118.5) |
Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC | 13vPnC / 13vPnC |
|---|---|---|
| Serotype 1 | 79 (65.3 to 94.6) | 76 (64.8 to 89.7) |
| Serotype 3 | 55 (47.2 to 64.0) | 55 (48.4 to 63.1) |
| Serotype 4 | 614 (489.8 to 768.8) | 487 (393.9 to 603.3) |
| Serotype 5 | 69 (56.2 to 84.2) | 57 (46.9 to 68.5) |
| Serotype 6A | 971 (771.0 to 1222.1) | 1169 (974.0 to 1403.0) |
| Serotype 6B | 1358 (1085.4 to 1700.2) | 1590 (1316.9 to 1919.8) |
| Serotype 7F | 222 (170.2 to 290.2) | 180 (138.1 to 233.8) |
| Serotype 9V | 187 (139.3 to 250.4) | 166 (124.2 to 220.8) |
| Serotype 14 | 265 (209.9 to 333.6) | 241 (194.4 to 299.1) |
| Serotype 18C | 918 (763.4 to 1104.3) | 1003 (850.2 to 1182.1) |
| Serotype 19A | 349 (299.7 to 405.5) | 341 (297.2 to 390.5) |
| Serotype 19F | 329 (265.6 to 408.6) | 322 (266.3 to 389.6) |
| Serotype 23F | 167 (130.9 to 213.0) | 309 (251.6 to 380.1) |
Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titers | 13vPnC / 13vPnC | 23vPS |
|---|---|---|
| Serotype 1 | 76 (64.9 to 89.5) | 55 (46.2 to 64.8) |
| Serotype 3 | 55 (47.9 to 62.0) | 49 (42.9 to 56.9) |
| Serotype 4 | 472 (383.5 to 580.2) | 203 (157.1 to 262.2) |
| Serotype 5 | 56 (46.6 to 67.7) | 36 (29.5 to 43.1) |
| Serotype 6B | 1565 (1306.1 to 1875.9) | 417 (330.5 to 526.7) |
| Serotype 7F | 185 (142.9 to 239.7) | 160 (123.5 to 207.9) |
| Serotype 9V | 158 (119.5 to 209.5) | 90 (67.8 to 119.7) |
| Serotype 14 | 238 (192.3 to 293.8) | 285 (228.9 to 354.3) |
| Serotype 18C | 975 (829.0 to 1147.3) | 481 (385.1 to 600.7) |
| Serotype 19A | 339 (296.4 to 386.9) | 200 (170.0 to 234.4) |
| Serotype 19F | 311 (257.1 to 375.9) | 214 (174.3 to 262.8) |
| Serotype 23F | 310 (254.1 to 378.0) | 43 (34.2 to 53.5) |
Antibody geometric mean titer as measured by OPA assay for the 6A serotype. Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.
| geometric mean titer | 13vPnC / 13vPnC | 23vPS |
|---|---|---|
| Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0) | 1134 (943.6 to 1363.7) | 94 (74.1 to 118.5) |
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
| percentage of participants | 13vPnC | 23vPS |
|---|---|---|
| Redness: Any (n=306, 324) | 10.8 | 22.2 |
| Redness: Mild (n=304, 311) | 9.5 | 13.5 |
| Redness: Moderate (n=301, 314) | 4.7 | 11.5 |
| Redness: Severe (n=299, 310) | 1.7 | 4.8 |
| Swelling: Any (n=307, 333) | 10.4 | 23.1 |
| Swelling: Mild (n=305, 315) | 8.9 | 14.0 |
| Swelling: Moderate (n=299, 323) | 4.0 | 13.6 |
| Swelling: Severe (n=297, 310) | 0.0 | 4.8 |
| Pain: Any (n=362, 383) | 51.7 | 58.5 |
| Pain: Mild (n=359, 377) | 50.1 | 54.1 |
| Pain: Moderate (n=306, 330) | 7.5 | 23.6 |
| Pain: Severe (n=299, 306) | 1.3 | 2.3 |
| Limitation of arm movement: Any (n=313, 326) | 10.5 | 27.6 |
| Limitation of arm movement: Mild (n=312, 322) | 10.3 | 25.2 |
| Limitation of arm movement: Moderate (n=297, 303) | 0.3 | 2.6 |
| Limitation of arm movement: Severe (n=298, 305) | 0.7 | 3.0 |
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
| percentage of participants | 13vPnC | 13vPnC / 13vPnC |
|---|---|---|
| Redness: Any (n=185, 185) | 9.7 | 12.4 |
| Redness: Mild (n=182, 182) | 8.2 | 6.0 |
| Redness: Moderate (n=182, 182) | 4.4 | 7.1 |
| Redness: Severe (n=179, 179) | 1.1 | 1.7 |
| Swelling: Any (n=185, 185) | 9.2 | 10.8 |
| Swelling: Mild (n=182, 182) | 6.6 | 8.8 |
| Swelling: Moderate (n=179, 179) | 3.4 | 2.8 |
| Swelling: Severe (n=177, 177) | 0.0 | 0.0 |
| Pain: Any (n=258, 258) | 55.0 | 57.4 |
| Pain: Mild (n=251, 251) | 53.0 | 54.2 |
| Pain: Moderate (n=187, 187) | 8.6 | 11.2 |
| Pain: Severe (n=179, 179) | 1.7 | 0.6 |
| Limitation of arm movement: Any (n=195, 195) | 9.7 | 13.3 |
| Limitation of arm movement: Mild (n=194, 194) | 9.3 | 13.4 |
| Limitation of arm movement: Moderate (n=178, 178) | 0.6 | 0.6 |
| Limitation of arm movement: Severe (n=178, 178) | 0.6 | 0.0 |
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
| percentage of participants | 23vPS | 13vPnC / 13vPnC |
|---|---|---|
| Redness: Any (n=324, 236) | 22.2 | 12.7 |
| Redness: Mild (n=311, 233) | 13.5 | 6.9 |
| Redness: Moderate (n=314, 231) | 11.5 | 6.9 |
| Redness: Severe (n=310, 227) | 4.8 | 1.8 |
| Swelling: Any (n=333, 236) | 23.1 | 12.3 |
| Swelling: Mild (n=315, 234) | 14.0 | 10.3 |
| Swelling: Moderate (n=323, 229) | 13.6 | 3.5 |
| Swelling: Severe (n=310, 227) | 4.8 | 0.9 |
| Pain: Any (n=383, 297) | 58.5 | 58.2 |
| Pain: Mild (n=377, 291) | 54.1 | 54.3 |
| Pain: Moderate (n=330, 239) | 23.6 | 13.0 |
| Pain: Severe (n=306, 226) | 2.3 | 0.4 |
| Limitation of arm movement: Any (n=326, 247) | 27.6 | 16.2 |
| Limitation of arm movement: Mild (n=322, 245) | 25.2 | 15.5 |
| Limitation of arm movement: Moderate (n=303, 228) | 2.6 | 0.9 |
| Limitation of arm movement: Severe (n=305, 228) | 3.0 | 0.9 |
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
| percentage of participants | 13vPnC / 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Redness: Any (n=236, 228) | 12.7 | 10.1 |
| Redness: Mild (n=233, 226) | 6.9 | 8.8 |
| Redness: Moderate (n=231, 223) | 6.9 | 3.6 |
| Redness: Severe (n=227, 222) | 1.8 | 0.9 |
| Swelling: Any (n=236, 241) | 12.3 | 14.1 |
| Swelling: Mild (n=234, 236) | 10.3 | 11.9 |
| Swelling: Moderate (n=229, 229) | 3.5 | 4.8 |
| Swelling: Severe (n=227, 222) | 0.9 | 0.5 |
| Pain: Any (n=297, 302) | 58.2 | 56.6 |
| Pain: Mild (n=291, 297) | 54.3 | 53.5 |
| Pain: Moderate (n=239, 236) | 13.0 | 13.1 |
| Pain: Severe (n=226, 221) | 0.4 | 0.9 |
| Limitation of arm movement: Any (n=247, 251) | 16.2 | 19.9 |
| Limitation of arm movement: Mild (n=245, 249) | 15.5 | 18.9 |
| Limitation of arm movement: Moderate (n=228, 222) | 0.9 | 0.9 |
| Limitation of arm movement: Severe (n=228, 222) | 0.9 | 1.4 |
Local reactions reported in electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
| percentage of participants | 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Redness: Any (n=306, 228) | 10.8 | 10.1 |
| Redness: Mild (n=304, 226) | 9.5 | 8.8 |
| Redness: Moderate (n=301, 223) | 4.7 | 3.6 |
| Redness: Severe (n=299, 222) | 1.7 | 0.9 |
| Swelling: Any (n=307, 241) | 10.4 | 14.1 |
| Swelling: Mild (n=305, 236) | 8.9 | 11.9 |
| Swelling: Moderate (n=299, 229) | 4.0 | 4.8 |
| Swelling: Severe (n=297, 222) | 0.0 | 0.5 |
| Pain: Any (n=362, 302) | 51.7 | 56.6 |
| Pain: Mild (n=359, 297) | 50.1 | 53.5 |
| Pain: Moderate (n=306, 236) | 7.5 | 13.1 |
| Pain: Severe (n=299, 221) | 1.3 | 0.9 |
| Limitation of arm movement: Any (n=313, 251) | 10.5 | 19.9 |
| Limitation of arm movement: Mild (n=312, 249) | 10.3 | 18.9 |
| Limitation of arm movement: Moderate (n=297, 222) | 0.3 | 0.9 |
| Limitation of arm movement: Severe (n=298, 222) | 0.7 | 1.4 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
| percentage of participants | 13vPnC | 23vPS |
|---|---|---|
| Fever: Any ≥38 degrees C (n=299, 309) | 1.0 | 4.2 |
| Fever: Mild ≥38 but <38.5 degrees C (n=299, 303) | 1.0 | 2.0 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=297,301) | 0.0 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C (n=297, 301) | 0.0 | 0.3 |
| Potentially life-threatening >40C (n=297, 307) | 0.0 | 2.0 |
| Fatigue (n=350, 367) | 34.0 | 43.3 |
| Headache (n=329, 331) | 23.7 | 26.0 |
| Chills (n=305, 312) | 7.9 | 11.2 |
| Rash (n=303, 323) | 7.3 | 16.4 |
| Vomiting (n=300, 304) | 1.7 | 1.3 |
| Decreased appetite (n=317, 313) | 10.4 | 11.5 |
| New muscle pain (n=345, 358) | 36.8 | 44.7 |
| Aggravated muscle pain (n=320, 334) | 20.6 | 27.5 |
| New joint pain (n=310, 323) | 12.6 | 14.9 |
| Aggravated joint pain (n=310, 322) | 11.6 | 16.5 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
| percentage of participants | 13vPnC | 13vPnC / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=179, 179) | 1.7 | 2.2 |
| Fever: Mild ≥38 but <38.5 degrees C (n=179, 179) | 1.7 | 0.6 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=177,177) | 0.0 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C (n=177, 177) | 0.0 | 0.6 |
| Potentially life-threatening >40C (n=177, 177) | 0.0 | 1.1 |
| Fatigue (n=215, 215) | 33.5 | 28.4 |
| Headache (n=200, 200) | 23.0 | 19.0 |
| Chills (n=182, 182) | 9.3 | 4.4 |
| Rash (n=183, 183) | 8.2 | 6.0 |
| Vomiting (n=178, 178) | 1.1 | 0.0 |
| Decreased appetite (n=190, 190) | 8.4 | 7.9 |
| New muscle pain (n=219, 219) | 37.9 | 35.6 |
| Aggravated muscle pain (n=198, 198) | 20.7 | 16.2 |
| New joint pain (n=187, 187) | 11.2 | 7.5 |
| Aggravated joint pain (n=188, 188) | 11.2 | 10.1 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
| percentage of participants | 23vPS | 13vPnC / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=309, 229) | 4.2 | 3.5 |
| Fever: Mild ≥38 but <38.5 degrees C (n=303, 227) | 2.0 | 0.9 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=301,227) | 0.0 | 0.9 |
| Fever: Severe ≥39 but ≤40 degrees C (n=301, 226) | 0.3 | 0.4 |
| Potentially life-threatening >40C (n=307, 227) | 2.0 | 1.3 |
| Fatigue (n=367, 255) | 43.3 | 28.6 |
| Headache (n=331, 246) | 26.0 | 19.1 |
| Chills (n=312, 234) | 11.2 | 7.3 |
| Rash (n=323, 232) | 16.4 | 6.0 |
| Vomiting (n=304, 226) | 1.3 | 0.4 |
| Decreased appetite (n=313, 237) | 11.5 | 8.9 |
| New muscle pain (n=358, 260) | 44.7 | 34.6 |
| Aggravated muscle pain (n=334, 245) | 27.5 | 18.0 |
| New joint pain (n=323, 238) | 14.9 | 10.5 |
| Aggravated joint pain (n=322, 239) | 16.5 | 12.6 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
| percentage of participants | 13vPnC / 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=229, 224) | 3.5 | 2.2 |
| Fever: Mild ≥38 but <38.5 degrees C (n=227, 224) | 0.9 | 1.8 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=227,221) | 0.9 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C (n=226, 222) | 0.4 | 0.5 |
| Potentially life-threatening >40C (n=227, 221) | 1.3 | 0.5 |
| Fatigue (n=255, 265) | 28.6 | 34.3 |
| Headache (n=246, 248) | 19.1 | 22.6 |
| Chills (n=234, 233) | 7.3 | 9.9 |
| Rash (n=232, 226) | 6.0 | 7.1 |
| Vomiting (n=226, 226) | 0.4 | 3.1 |
| Decreased appetite (n=237, 230) | 8.9 | 7.4 |
| New muscle pain (n=260, 263) | 34.6 | 35.0 |
| Aggravated muscle pain (n=245, 248) | 18.0 | 21.0 |
| New joint pain (n=238, 234) | 10.5 | 12.0 |
| Aggravated joint pain (n=239, 231) | 12.6 | 11.7 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
| percentage of participants | 13vPnC | 23vPS / 13vPnC |
|---|---|---|
| Fever: Any ≥38 degrees C (n=299, 224) | 1.0 | 2.2 |
| Fever: Mild ≥38 but <38.5 degrees C (n=299, 224) | 1.0 | 1.8 |
| Fever: Moderate ≥38.5 but <39 degrees C(n=297,221) | 0.0 | 0.0 |
| Fever: Severe ≥39 but ≤40 degrees C (n=297, 222) | 0.0 | 0.5 |
| Potentially life-threatening >40C (n=297, 221) | 0.0 | 0.5 |
| Fatigue (n=350, 265) | 34.0 | 34.3 |
| Headache (n=329, 248) | 23.7 | 22.6 |
| Chills (n=305, 233) | 7.9 | 9.9 |
| Rash (n=303, 226) | 7.3 | 7.1 |
| Vomiting (n=300, 226) | 1.7 | 3.1 |
| Decreased appetite (n=317, 230) | 10.4 | 7.4 |
| New muscle pain (n=345, 263) | 36.8 | 35.0 |
| Aggravated muscle pain (n=320, 248) | 20.6 | 21.0 |
| New joint pain (n=310, 234) | 12.6 | 12.0 |
| Aggravated joint pain (n=310, 231) | 11.6 | 11.7 |
Collected over Events assessed until approximately 1 month after each vaccination. AEs collected up to 43 days after Vax 2 / Year 1; SAEs collected up to 194 days after Vax 2 / Year 1. Local Reactions and Systemic Events assessed within 14 days of each vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC (Vax 1 / Year 0) 1 Month After Vaccination | — | 3/463 (0.6%) | 234/463 (50.5%) |
| 23vPS (Vax 1 / Year 0) 1 Month After Vaccination | — | 8/473 (1.7%) | 275/473 (58.1%) |
| 13vPnC 6-M FU (Vax 1 / Year 0) | — | 27/463 (5.8%) | 60/463 (13%) |
| 23vPS 6-M FU (Vax 1 / Year 0) | — | 26/473 (5.5%) | 59/473 (12.5%) |
| 13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | — | 4/391 (1%) | 191/391 (48.8%) |
| 23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | — | 7/404 (1.7%) | 189/404 (46.8%) |
| 13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1) | — | 17/391 (4.3%) | 29/391 (7.4%) |
| 23vPS / 13vPnC 6-M FU (Vax 2 / Year 1) | — | 21/404 (5.2%) | 30/404 (7.4%) |
| Event | 13vPnC (Vax 1 / Year 0) 1 Month After Vaccination | 23vPS (Vax 1 / Year 0) 1 Month After Vaccination | 13vPnC 6-M FU (Vax 1 / Year 0) | 23vPS 6-M FU (Vax 1 / Year 0) | 13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | 23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | 13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1) | 23vPS / 13vPnC 6-M FU (Vax 2 / Year 1) |
|---|---|---|---|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/463 | 2/473 | 3/463 | 4/473 | 1/391 | 0/404 | 3/391 | 0/404 |
| Atrial fibrillationCardiac disorders | 1/463 | 0/473 | 1/463 | 0/473 | 0/391 | 0/404 | 0/391 | 3/404 |
| Angina pectorisCardiac disorders | 1/463 | 1/473 | 3/463 | 0/473 | 1/391 | 0/404 | 0/391 | 0/404 |
| BradycardiaCardiac disorders | 0/463 | 0/473 | 0/463 | 0/473 | 0/391 | 0/404 | 2/391 | 0/404 |
| PneumoniaInfections and infestations | 0/463 | 1/473 | 0/463 | 1/473 | 0/391 | 0/404 | 0/391 | 2/404 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/463 | 0/473 | 0/463 | 2/473 | 0/391 | 0/404 | 0/391 | 2/404 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/463 | 0/473 | 0/463 | 1/473 | 0/391 | 1/404 | 0/391 | 2/404 |
| Coronary artery diseaseCardiac disorders | 0/463 | 0/473 | 2/463 | 1/473 | 0/391 | 0/404 | 0/391 | 0/404 |
| Myocardial infarctionCardiac disorders | 0/463 | 0/473 | 2/463 | 1/473 | 0/391 | 0/404 | 0/391 | 0/404 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/463 | 0/473 | 0/463 | 2/473 | 0/391 | 1/404 | 1/391 | 0/404 |
| Event | 13vPnC (Vax 1 / Year 0) 1 Month After Vaccination | 23vPS (Vax 1 / Year 0) 1 Month After Vaccination | 13vPnC 6-M FU (Vax 1 / Year 0) | 23vPS 6-M FU (Vax 1 / Year 0) | 13vPnC / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | 23vPS / 13vPnC (Vax 2 / Year 1) 1 Month After Vaccination | 13vPnC / 13vPnC 6-M FU (Vax 2 / Year 1) | 23vPS / 13vPnC 6-M FU (Vax 2 / Year 1) |
|---|---|---|---|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 187/362 | 224/383 | — | — | 173/297 | 171/302 | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 142/258 | 0/473 | — | — | 148/258 | 0/404 | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 180/359 | 204/377 | — | — | 158/291 | 159/297 | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 133/251 | 0/473 | — | — | 136/251 | 0/404 | — | — |
| New generalized muscle painGeneral disorders | 127/345 | 160/358 | — | — | 90/260 | 92/263 | — | — |
| FatigueGeneral disorders | 119/350 | 159/367 | — | — | 73/255 | 91/265 | — | — |
| New generalized muscle painGeneral disorders | 83/219 | 0/473 | — | — | 78/219 | 0/404 | — | — |
| FatigueGeneral disorders | 72/215 | 0/473 | — | — | 61/215 | 0/404 | — | — |
| Limitation of arm movement (Any)Skin and subcutaneous tissue disorders | 33/313 | 90/326 | — | — | 40/247 | 50/251 | — | — |
| Aggravated generalized muscle painGeneral disorders | 66/320 | 92/334 | — | — | 44/245 | 52/248 | — | — |
| Age Continuous(years) | 13vPnC | 23vPS | Total |
|---|---|---|---|
| Mean | 76.7 ± 4.6 | 76.7 ± 4.5 | 76.7 ± 4.6 |
| Sex: Female, Male(Participants) | 13vPnC | 23vPS | Total |
|---|---|---|---|
| Female | 221 | 235 | 456 |
| Male | 242 | 238 | 480 |
The record gives a start of Nov 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →